News AtriCure, Inc.

Equities

ATRC

US04963C2098

Market Closed - Nasdaq Other stock markets 01:30:00 30/04/2024 am IST			5-day change	1st Jan Change
23.37 ^USD	+0.86%		+2.91%	-34.52%

23/04	Oppenheimer Upgrades AtriCure to Outperform, Price Target at $32	MT
18/04	AtriCure, Inc. Announces Launch of the CryoSPHERE®?+ Probe for Post-Operative Pain Management	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Upgrades AtriCure to Outperform, Price Target at $32	23/04	MT
AtriCure Announces Launch of the cryoSPHERE+ Probe for Post-Operative Pain Management	19/04	AQ
AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management	18/04	BU
AtriCure, Inc. Announces Launch of the CryoSPHERE®?+ Probe for Post-Operative Pain Management	18/04	CI
AtriCure to Announce First Quarter 2024 Financial Results	10/04	BU
AtriCure to Participate in the 23rd Annual Needham Virtual Healthcare Conference	26/03	BU
AtriCure Insider Sold Shares Worth $307,510, According to a Recent SEC Filing	07/03	MT
Atricure, Inc. Appoints Shlomi Nachman as Director, Member of Each of the Board?s Strategy Committee and Compliance, Quality and Risk Committee	27/02	CI
UBS Adjusts AtriCure Price Target to $58 From $57, Maintains Buy Rating	16/02	MT
Stifel Adjusts Price Target on AtriCure to $42 From $50, Maintains Buy Rating	16/02	MT
Needham Adjusts Price Target on AtriCure to $46 From $44, Keeps Buy Rating	16/02	MT
AtriCure Q4 Loss Widens, Revenue Rises; 2024 Guidance Set	16/02	MT
Transcript : AtriCure, Inc., Q4 2023 Earnings Call, Feb 15, 2024	16/02
Earnings Flash (ATRC) ATRICURE Reports Q4 Revenue $106.5M, vs. Street Est of $104.2M	16/02	MT
AtriCure: Q4 Earnings Snapshot	16/02	AQ
AtriCure Reports Fourth Quarter 2023 and Full Year 2023 Financial Results	16/02	BU
Atricure, Inc. Provides Earnings Guidance for 2024	16/02	CI
AtriCure, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	16/02	CI
AtriCure to Announce Fourth Quarter and Full Year 2023 Financial Results and Participate in 2024 BTIG Medical Technology Conference	25/01	BU
UBS Adjusts AtriCure Price Target to $57 From $56, Maintains Buy Rating	22/01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News AtriCure, Inc.

Equities

ATRC

US04963C2098

Summary

Filters